

Curriculum vitae: Tina Svenstrup Poulsen – August 2023

Navn: Tina Svenstrup Poulsen

Autorisations-ID: 00QBF

Uddannelser:

1995: Cand.med. ved Odense Universitet
2005: Ph.d.-grad udgående fra Syddansk Universitet: “*Aspirin Resistance. Definition, Prevalence and Prognostic Implications in Patients with Cardiovascular Disease.*”
2010: Speciallæge i Intern Medicin: Kardiologi
2016: Master of Public Management (MPM) ved Syddansk Universitet

Ansættelser:

01.08.95-31.01.96: Turnus, Medicinsk afdeling, Ringkøbing Sygehus
01.02.96-31.07.96: Turnus, Medicinsk afdeling, Ringkøbing Sygehus
01.08.96-01.08.96: Reservelæge, Nuklearmedicinsk afdeling, OUH
01.04.97-31.07.97: Reservelæge, Medicinsk afdeling, Kolding Sygehus
01.08.97-31.01.98: Turnus, Almen Praksis i Ulfborg
01.02.98-31.05.98: Reservelæge, Medicinsk afdeling C, OUH
01.06.98-25.12.98: Barselsorlov
26.12.98-31.01.00: Reservelæge, Medicinsk afdeling C, OUH
01.02.00-31.01.01: Reservelæge, Hjertemedicinsk Afdeling B, OUH
01.02.01-31.08.05: Ph.d.-studerende, Hjertemedicinsk Afdeling B, OUH
01.09.05-30.08.07: HU-læge, Medicinsk afdeling, Vejle Sygehus
01.09.07-31.08.09: HU-læge, Hjertemedicinsk Afdeling B, OUH
01.08.09-31.08.10: HU-læge, Hjertemedicinsk Afdeling, Vejle Sygehus
01.09.10-30.11.10: Afdelingslæge, Hjertemedicinsk Afdeling B, OUH
01.12.10-30.11.11: Afdelingslæge, Hjertemedicinsk Afdeling B, Rigshospitalet
01.12.11-01.01.14: Overlæge, Hjertemedicinsk Afdeling B, OUH
2012-: Klinisk lektor ved Syddansk Universitet
2014-: Ledende overlæge (fra 2022 ændret titel til cheflæge), Hjertemedicinsk Afdeling B, OUH

Ledelse og tillidserhverv:

2005-2009 Medlem af bestyrelsen Foreningen af Yngre Cardiologer (FYC)
2005-2010 Medlem af det regionale videreuddannelsesudvalg i region Syddanmark
2006-2008 Formand for Foreningen af Yngre Cardiologer (FYC)
2006-2008 Medlem af bestyrelsen for Dansk Cardiologisk Selskab
2006-2008 Medlem af kursus og CME-udvalget under Dansk Cardiologisk Selskab
2007-2010 Medlem af NBV-udvalget under Dansk Cardiologisk Selskab
2014 Medlem af fagudvalget under RADS vedr antitrombotisk behandling
2014-2023 Medlem af specialerådet i region Syddanmark (heraf formand i 2 år)
2020-2022 Formand for HjerterFyn (sammenslutning af de 9 fynske kommuner, almen praksis og de kardiologiske sygehusafdelinger)
2022-2023: Formand for region Syddanmarks udbud indenfor patientmonitorering

Publikationer:

1. Lambrecht S, Sarkisian L, Saaby L, **Poulsen TS**, Gerke O, Hosbond S, Diederichsen ACP, Thygesen K, Mickley H. Different causes of death in patients with myocardial infarction type 1, type 2, and myocardial injury. *Am J Med* 2018;131:548-554
2. Sarkisian L, Saaby L, **Poulsen TS**, Gerke O, Jangaard N, Hosbond S, Diederichsen AC, Thygesen K, Mickley H. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. *Am J Med* 2016;129:446.e5-446.e21
3. Sarkisian L, Saaby L, **Poulsen TS**, Gerke O, Hosbond S, Jangaard N, Diederichsen AC, Thygesen K, Mickley H. Prognostic Impact of Myocardial Injury Related to Various Cardiac and Noncardiac Conditions. *Am J Med* 2016;129:506-514
4. D'Souza M, Sarkisian L, Saaby L, **Poulsen TS**, Gerke O, Larsen TB, Diederichsen AC, Jangaard N, Diederichsen SZ, Hosbond S, Hove J, Thygesen K, Mickley H. Diagnosis of unstable angina pectoris has declined markedly with the advent of more sensitive troponin assays. *Am J Med* 2015;128:852-60
5. Saaby L, **Poulsen TS**, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, Gerke O, Hallas J, Thygesen K, Mickley H. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. *Am J Med* 2014;127:295-302
6. Jørgensen PH, Nybo M, Jensen MK, Mortensen PE, **Poulsen TS**, Diederichsen AC, Mickley H. Optimal cut-off value for cardiac troponin I in ruling out Type 5 myocardial infarction. *Interact Cardiovasc Thorac Surg* 2014;18:544-50
7. Hosbond SE, Diederichsen AC, Pedersen L, Rasmussen LM, Munkholm H, Gerke O, **Poulsen TS**, Mickley H. Lipocalin-type prostaglandin D synthase is not a biomarker of atherosclerotic manifestations. *Scand J Clin Lab Invest* 2014;74:219-27
8. Hosbond SE, Diederichsen AC, Saaby L, Rasmussen LM, Lambrechtsen J, Munkholm H, Sand NP, Gerke O, **Poulsen TS**, Mickley H. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? *Atherosclerosis* 2014;236:230-6
9. D'Souza M, Saaby L, **Poulsen TS**, Diederichsen AC, Hosbond S, Diederichsen SZ, Larsen TB, Schmidt H, Gerke O, Hallas J, Gislason G, Thygesen K, Mickley H. Comparison of mortality in patients with acute myocardial infarction accidentally admitted to non-cardiology departments versus that in patients admitted to coronary care units. *Am J Cardiol* 2014;114:1151-7
10. Saaby L, **Poulsen TS**, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. *Am J Med* 2013;126:789-97
11. Vinholt PJ, Overgaard M, Diederichsen AC, Mickley H, **Poulsen TS**, Sand NP, Nybo M, Rasmussen LM. An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma. *Thromb Res* 2013;131:396-400
12. Barascuk N, Genovese F, Larsen L, Byrjalsen I, Zheng Q, Sun S, Hosbond S, **Poulsen TS**, Diederichsen A, Jensen JM, Mickley H, Register TC, Rasmussen LM, Leeming DJ, Christiansen C, Karsdal MA. A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. *Int J Clin Exp Med* 2013;6:174-84
13. Wulf-Johansson H, Lock Johansson S, Schlosser A, Trommelholt Holm A, Rasmussen LM, Mickley H, Diederichsen AC, Munkholm H, **Poulsen TS**, Tornøe I, Nielsen V, Marcussen N, Vestbo J, Sækmoose SG, Holmskov U, Sorensen GL. Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. *PLoS One*. 2013;8:e82243.
14. Decker Christensen T, **Poulsen TS**, Husted S, Münster AM. New and old anticoagulant therapy. *Ugeskr Laeger*. 2013;175:816

15. Hosbond SE, **Poulsen TS**, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. *Scand Cardiovasc J* 2012;46:203-11
16. Poulsen MK, Nybo M, Dahl J, Hosbond S, **Poulsen TS**, Johansen A, Højlund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. *Cardiovasc Diabetol* 2011;10:76
17. Al-Dakheel Z, Larsen SR, **Poulsen TS**, Mickley H. Lack of consensus in biomarker measurement to diagnose PCI-related myocardial infarction. *Scand Cardiovasc J* 2009;43:152-7
18. Løfgren B, Wahlgreen C, Hoffmann AM, **Poulsen TS**, Krarup NH. In-hospital resuscitation with automated external defibrillator. *Ugeskr Laeger* 2009;171:308-10
19. Terkelsen CJ, Oxvig C, Nørgaard BL, Glerup S, **Poulsen TS**, Lassen JL, Moestrup SK, Møller HJ, Thuesen L, Falk E, Nielsen TT, Henning R Andersen. Temporal Course of Pregnancy-Associated Plasma Protein-A in Angioplasty-Treated ST-Elevation Myocardial Infarction Patients and Potential Significance of Concomitant Heparin Administration. *Am J Cardiol* 2009; 103:29-35
20. Hjorth Madsen E, Christiansen MK, Schmidt EB, **Poulsen TS**, Kristensen SR. Effect of exercise on platelet activation during aspirin or clopidogrel intake in healthy men. *Platelets* 2009 ;20:177-82
21. Mortensen J, **Poulsen TS**, Grove EL, Refsgaard J, Nielsen HL, Pedersen SB, Thygesen SS, Hvas AM, Kristensen SD. Monitoring aspirin therapy with the Platelet Function Analyzer-100. *Scand J Clin Invest* 2008;24:1-7
22. **Poulsen TS**, Jorgensen B, Korsholm L, Bjorn Licht P, Haghfelt T, Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. *Thromb Res* 2007;119:555-62
23. **Poulsen TS**, Kristensen SR, Korsholm L, Haghfelt T, Jørgensen B, Licht PB, Mickley H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. *Thromb Res* 2007;120:477-84
24. Overgaard K, **Poulsen TS**, Husted SE. Antithrombotic therapy in ischemic stroke and transient ischemic attack. *Ugeskr Laeger* 2007;169:3379-82
25. Mortensen J, **Poulsen TS**, Refsgaard J, Kristensen SD. Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin no-responders. *Platelets* 2007;18:389-90
26. **Poulsen TS**, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, Mickley H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. *Thromb Res* 2006;120:477-84
27. Tjerrild SB, Jakobsen AM, **Poulsen TS**, Andersen LI, Mickley H Coronary angioplasty and coronary artery bypass surgery in older patients. Incidence, complications and mortality, 1999-2003. *Ugeskr Laeger* 2006;168:3521-5
28. **Poulsen TS**, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. *Thromb Res* 2006;120:161-72
29. Kjaer J, Larsen CH, **Poulsen TS**, Møller JE, Mickley H. Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome. *Ugeskr Laeger* 2006;168:3209-14
30. **Poulsen TS**, Kastrup A, Mickley H Is aspirin resistance or female gender associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention? *J Am Coll Cardiol* 2005;45:635-6

31. **Poulsen TS**, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. *Basic Clin Pharmacol Toxicol* 2005;96:103-10
32. Vinholt P, **Poulsen TS**, Korsholm L, Kristensen SR, Hallas J, Damkier P, Mickley H. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. *Thromb Haemost* 2005;94:438-43
33. **Poulsen TS**, Mickley H, Damkier P. Interaction between clopidogrel and statins? *Ugeskr Laeger* 2004;166:2370-1
34. **Poulsen TS**, Mickley H. Is the antiplatelet effect of aspirin affected by systemic inflammation? *Ann Hematol* 2004;83:728
35. Mickley H, **Poulsen TS**. Use of sildenafil is safe in men with congestive heart failure. *Arch Intern Med* 2004;164:2068
36. Mickley H, **Poulsen TS**, Højlund-Carlsen PF, Andersen LI. Treatment of stable ischemic heart disease: drugs, balloon or surgery? *Ugeskr Laeger* 2004;166:896-8

I perioden 2007-2014 desuden reviewer ved følgende tidsskrifter:

- JACC
- Cardiology
- Coronary Artery Disease
- Thrombosis Research
- Scandinavian Cardiovascular Journal

Internationale foredrag:

1. **Poulsen TS**. PFA-100 and aspirin resistance in patients with acute myocardial infarction. *Eurothrombosis Science 2006: Platelets and Thrombosis*. ESC Working Group Thrombosis Meeting, 2006, Ebeltoft. Invited speaker.
2. **Poulsen TS**. Can resistant patients be timely recognised? *European Council of Cardiovascular Research Meeting*, 2006, Nice. Invited speaker.
3. **Poulsen TS**. Rethrombosis after myocardial infarction. Myths and facts of aspirin resistance. *Nordic Coagulation Meeting*, 2005, København. Invited speaker.
4. **Poulsen TS**. Aspirin Resistance. "4th International Summit on Atherosclerosis". 2004, København. Invited speaker.
5. **Poulsen TS**. The PFA-100 in monitoring aspirin therapy – how far are we? *A Nordic User Seminar for the Coagulation Laboratory*, 2004, Malmø. Invited speaker.
6. **Poulsen TS**. The clinical importance of aspirin resistance in acute myocardial infarction. *The 5th International Congress on Coronary Artery Disease – from Prevention to Intervention*, 2003, Firenze.
7. **Poulsen TS**. Aspirin resistance in patients with acute myocardial infarction: Is it of any clinical importance. *The European Society of Cardiology Congress 2003*, Wien. Presentation as a Featured Research Session and at the following press conference.
8. **Poulsen TS**. Aspirin resistance and acute myocardial infarction. *XIX Nordic Congress of Cardiology*, 2003, Odense.

Vejleder:

Vejleder for 2 gennemførte ph.d.-afhandlinger

Vejleder for 2 gennemførte et-årige prægraduate forskningsforløb

Vejleder for 4 gennemførte prægraduate forskningsopgaver

Bedømmer på 1 prægraduate forskningsforløb

Priser:

2008: Direktør Viggo E. Thiesen and Hustrus Legat af Dansk Cardiologisk Selskab

2010: Dansk Cardiologisk Selskab og Foreningen af Yngre Cardiologers Uddannelsespris